Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C treatment

    Effective direct-acting antiviral or 'DAA' medicines, used without interferon, can now cure most people with hepatitis C. This includes people who previously were considered to be more difficult...

    From: Booklets

    Information level Level 2
  • Medications for hepatitis C

    DAAs target different steps of HCV reproduction. These include HCV protease inhibitors, polymerase inhibitors and NS5A inhibitors. Recommended regimens include at least two drugs that work in different...

    From: Booklets

    Information level Level 2
  • Treatment for people with HIV and HCV co-infection

    In the UK, standards for HIV treatment and care are set and monitored by the British HIV Association (BHIVA), the professional association for HIV doctors and other healthcare...

    From: Booklets

    Information level Level 2
  • Hepatitis C and HIV

    Hepatitis C is a blood-borne infection that is transmitted in some of the same ways as HIV.Over time untreated hepatitis C...

    From: Factsheets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • Egypt proposes plan to treat African Hepatitis C patients

    Minister of Health Hala Zayed unveiled an Egyptian initiative to treat African people from Hepatitis C, starting with the Nile Basin countries who have an estimated 3.7 million hepatitis C patients, representing 30 percent of the total number of infected people in Africa.

    16 January 2019 | Egypttoday
  • Pakistan has 5 million hepatitis patients

    There are currently five million hepatitis patients in Pakistan and the country is listed as the most affected country after Egypt in the world.

    03 January 2019 | The Nation
  • New strains of hepatitis C found in Africa

    The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa. The discovery suggests certain antiviral drugs used in the West may be less effective against these strains, and local clinical trials of patients are urgently needed. Published in Hepatology, the study could inform hepatitis C vaccine development and assist the World Health Organisation's aim of eliminating hepatitis C globally.

    17 December 2018 | Eurekalert Inf Dis
  • New treatment could see NZ eradicate Hepatitis C in next 20 years

    It's hoped a new treatment for Hepatitis C will put New Zealand on track to eradicate the virus within 20 years. Pharmac has announced funding for a medication that can cure all types of it.

    17 December 2018 | Newshub
  • Rwanda launches 5-year campaign to eradicate hepatitis C

    Rwanda on Tuesday launched a five-year plan to detect and treat hepatitis C virus as part of a campaign that aims at eliminating hepatitis C in the country.

    12 December 2018 | Xinhua
  • Moving on with my life: Getting cured of hepatitis C

    Interviews with people who have had successful treatment for hepatitis C & what it means for them. Made for the annual conference of the London Joint Working Group on Substance Use & Hepatitis C, Held at The Guildhall London on 3 December 2018.

    07 December 2018 | YouTube
  • Eliminating Hepatitis: A unique opportunity that shouldn't be missed

    Micro-elimination seeks to eliminate HCV in particular target populations, permitting rapid, focused action. It can also address inequities in service delivery by concentrating health system attention on stigmatised groups. Initiatives aimed at specific risk groups, such as men who have sex with men, migrants and drug users, already exist for HIV in so-called ‘Fast-Track’ cities, such as Amsterdam and Madrid and need to be adapted to include hepatitis.

    22 November 2018 | The Parliament Magazine
  • Vosevi safe, effective in ‘triple-infected’ patients with HCV, HBV, HIV

    The direct-acting antiviral Vosevi demonstrated an average sustained virologic response rate of 87% among patients who were “triple-infected” with hepatitis C genotype 3, hepatitis B and HIV, as presented at the American College of Gastroenterology Annual Meeting.

    15 October 2018 | Healio
  • Anti-virals cure up to 98% of hepatitis C patients since 2014

    The figures from the national treatment registry for Irish hepatitis C patients represent “a triumph of science”, Dr Diarmuid Houlihan, a hepatologist at St Vincent’s University Hospital told a conference in Dublin on Monday.

    09 October 2018 | Irish Times
  • What It Means for Gilead to Launch Its Own Generics for Hepatitis C Treatments

    There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies to mitigate the threat of biosimilars. They can just launch their own. Several large drug and biotech companies have done so in recent years, and this is what is being seen at Gilead Sciences Inc.

    25 September 2018 | 24/7 Wall St.
More news
Tell us why you visited aidsmap today
minimise

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?

close

Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email info@nam.org.uk.

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.